©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 102-108, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.102108

Nanotheranostics in Obesity and Diabetes: Dual Role in Early Detection and Precision Therapy

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

ABSTRACT

Obesity and type 2 diabetes (T2D) arise from complex, tissue-specific pathologies spanning adipose inflammation, ectopic lipid deposition, hepatic insulin resistance, and microvascular dysfunction. Conventional diagnostics detect late-stage complications and provide limited spatial resolution of disease activity, while therapeutics often lack tissue selectivity and dynamic control. Nanotheranostics as a single platform that integrate targeted imaging and therapy offers a route to earlier detection and precision intervention. Engineered nanoparticles can home to metabolically diseased tissues, amplify multimodal imaging signals, and release drugs in response to biochemical cues such as pH, enzymes, or redox gradients. By coupling quantification and treatment within the same construct, nanotheranostics enable dose individualization, on-treatment monitoring, and adaptive regimens guided by imaging readouts. This review outlines biological rationales for theranostic targeting in metabolic disease; surveys contrast chemistries and imaging modalities suited to adipose, liver, pancreas, muscle, and vasculature; details stimuli-responsive designs that synchronize drug release with pathologic microenvironments; and examines safety, manufacturability, and regulatory pathways. We propose clinical trial frameworks that incorporate quantitative imaging endpoints with glycemic and cardiometabolic outcomes, positioning nanotheranostics as complementary to incretins, SGLT2 inhibitors, and lifestyle interventions. If translated responsibly, nanotheranostics could shift obesity and T2D care from reactive management to proactive, image-guided precision therapy.

Keywords: nanotheranostics; metabolic imaging; targeted nanoparticles; adipose inflammation; insulin resistance; precision medicine; type 2 diabetes; image-guided therapy

INTRODUCTION

Obesity and type 2 diabetes are intertwined global epidemics characterized by chronic positive energy balance, adipose tissue remodeling, metabolic inflexibility, and progressive organ dysfunction[1–3]. Pathophysiology spans multiple scales: cellular mitochondrial stress and ER stress; tissue-level fibrosis, hypoxia, and immune infiltration; and systemic abnormalities in glucose, lipid, and hormone flux[4–6]. Clinically, standard diagnostics like fasting glucose, HbA1c, lipid panels, and anthropometrics capture late or averaged phenomena but provide little spatial or temporal resolution of the active disease biology inside adipose depots, the liver, skeletal muscle, or the microvasculature[7–9]. Imaging can add anatomical and functional information, yet routine modalities remain underused in metabolic care and seldom guide individualized therapy selection or dosing.

A central challenge is heterogeneity. Two individuals with similar BMI and HbA1c can harbor markedly different tissue pathologies: one dominated by visceral adipose inflammation and hepatic steatosis; another by skeletal muscle insulin resistance and microvascular rarefaction. Therapeutics likewise face distribution and tolerability constraints[10]. Incretin analogs yield potent glucose and weight benefits but suffer from dose-limiting gastrointestinal adverse effects; SGLT2 inhibitors are effective for cardio-renal protection but do not directly address organ-specific insulin resistance; and insulin itself is potent yet carries hypoglycemia and weight-gain risks when pharmacokinetics mismatch physiologic needs[11]. Precisely locating disease activity and matching it with tailored, controllable therapy could raise efficacy while lowering side effects [12, 13].

Nanotheranostics integrate diagnosis and therapy within the same nanoscale construct. By combining a targeting ligand, an imaging reporter (e.g., PET, MRI, photoacoustic, or fluorescence), and a therapeutic

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

payload (small molecule, peptide, nucleic acid, or biologic), such platforms can accumulate in diseased tissues, report on local biology, and release treatment in response to environmental triggers[14–16]. In metabolic disease, candidate cues include low-grade acidity from inflamed adipose, matrix metalloproteinase activity in remodeling tissue, elevated lipase activity in adipose microenvironments, oxidative stress, or glycation-associated changes. Spatially resolved imaging of these signals enables early detection and quantitative monitoring, while synchronous or subsequent therapy closes the loop between measurement and action.

The promise extends beyond targeting. Theranostics can operationalize adaptive care: an index scan quantifies depot or organ uptake, informing whether a patient qualifies for treatment; repeated imaging measures pharmacodynamic response and guides dose escalation or de-escalation; and if the same particle releases drug under defined conditions, therapy can be throttled by endogenous cues or external triggers (e.g., ultrasound)[15–17]. Such workflows mirror oncology's PET-guided regimens, now reimagined for metabolic medicine, where endpoints like insulin sensitivity, hepatic glucose production, or adipose inflammation could be imaged directly.

Translation requires rigorous attention to safety and manufacturability. Nanoparticles may be sequestered by the mononuclear phagocyte system, activate complement, or trigger anti-polymer antibodies after repeat dosing[18–21]. Imaging labels must be stable, bright, and safe at clinical doses; therapeutic loading must be consistent; and release kinetics must remain predictable across patient phenotypes[15, 17, 22, 23]. Regulatory pathways are tractable but complex, often treating theranostics as combination products requiring coordinated chemistry, manufacturing, and control strategies for both imaging and drug components.

This review synthesizes the design principles and clinical logic for nanotheranostics in obesity and diabetes. We begin with the biological and clinical rationale for organ- and pathway-specific targeting; survey imaging modalities and contrast platforms matched to metabolic tissues; discuss molecular ligands and biomarker integration; describe stimuli-responsive and externally triggered designs that synchronize diagnosis with therapy; and outline safety, manufacturing, and regulatory considerations unique to chronic metabolic indications. We close with clinical trial strategies and use cases from early detection of high-risk visceral adiposity to image-guided anti-steatotic and anti-inflammatory therapies, positioning nanotheranostics as an enabling layer that complements contemporary pharmacology and lifestyle care.

2. Imaging Modalities and Contrastable Nanoplatforms for Metabolic Tissues

Selecting the right imaging readout is foundational. Positron emission tomography (PET) offers sensitivity at picomolar tracer levels and quantitative whole-body mapping, well-suited for detecting active inflammation, oxidative stress, fatty acid uptake, or mitochondrial function[22, 24, 25]. Nanoparticles carrying PET isotopes (e.g., ^64Cu, ^89Zr, ^68Ga) can report on biodistribution and target engagement while co-delivering therapy, though isotope half-life must match particle kinetics. Magnetic resonance imaging (MRI) provides anatomy and function without ionizing radiation; superparamagnetic iron oxide or gadolinium-free T1 agents embedded in nanoparticles visualize liver, spleen, and inflamed adipose, and chemical shift–encoded MRI quantifies fat fraction that can be paired with theranostic deposition.

Photoacoustic imaging bridges optical contrast with ultrasound resolution, leveraging chromophores such as indocyanine green analogs or engineered dyes anchored to nanoparticles to interrogate superficial depots (e.g., subcutaneous adipose) and cutaneous microvasculature[26]. Ultrasound itself becomes diagnostic when particles are gas-generating or microbubble-decorated, enabling contrast-enhanced perfusion mapping and serving as an external trigger for release[27–29]. Near-infrared fluorescence allows intraoperative or superficial monitoring, useful for patch-based or microneedle theranostics.

Each modality has trade-offs. PET is exquisitely sensitive but requires radiochemistry and exposes patients to low radiation; MRI affords rich soft-tissue detail but demands higher contrast doses and longer scans; optical/photoacoustic are depth-limited yet convenient and repeatable; ultrasound is widely available and safe but provides indirect molecular information unless paired with targeted contrast[30]. Hybrid imaging PET/MRI or PET/CT can co-register molecular signals with anatomy, and dual-reporter nanoparticles enable cross-validation between modalities, increasing confidence in pharmacodynamic interpretation[30].

Contrast chemistry must be stable and safe under chronic use. Chelator–metal complexes need high kinetic inertness; dyes require resistance to photobleaching and metabolic degradation; and iron oxide cores must avoid long-term tissue accumulation[31]. For chronic diseases, repeatability is essential, arguing for tracers with short half-life or non-radioactive readouts for frequent monitoring, and for biodegradable carriers that clear predictably[31].

Operationally, imaging readouts should tie to actionable thresholds e.g., depot standardized uptake value above a cut-off triggers therapy; a 30% decline signals response; lack of change prompts switching[32]. Embedding these rules into protocols converts images into decisions. By aligning nanoparticle contrast with clinically accessible modalities and quantitative criteria, theranostics become not just elegant constructs but practical tools for metabolic care.

3. Targeting Ligands, Biomarkers, and Companion Diagnostics

Effective theranostics hinge on recognition elements that direct particles to relevant cells and matrices. Short peptides identified by in vivo phage display can home to adipose vascular endothelium, inflamed macrophages,

or fibrotic liver[33]. Galactose or N-acetylgalactosamine motifs target hepatocyte asialoglycoprotein receptors, supporting hepatic uptake useful in insulin resistance and steatosis. Integrin-binding sequences (e.g., RGD variants) engage angiogenic vasculature present in remodeling adipose depots[33]. Scavenger receptor ligands bias delivery to metabolically active macrophages that orchestrate adipose inflammation. For islet-adjacent niches, vascular cell adhesion molecule (VCAM-1) or E-selectin ligands may enrich peri-islet microenvironments undergoing immune activation[34].

Biomarker integration elevates precision. Circulating panels such as adipokines, cytokines, ketone bodies, and exosomal microRNAs can serve as gatekeepers determining who undergoes imaging. Imaging then provides spatial confirmation and quantification. Transcriptomic or proteomic signatures from occasional biopsies calibrate imaging signals, forming companion diagnostics that predict response. For example, high matrix metalloproteinase activity measured in serum and imaging could qualify patients for MMP-responsive theranostics targeting fibrosing liver; elevated ROS signatures might indicate suitability for redox-responsive adipose constructs.

Specificity must be balanced with practicality. High-affinity antibodies offer strong targeting but may complicate manufacturing and immunogenicity; peptides and aptamers are smaller, synthetically accessible, and often sufficient for depot-level enrichment. Multivalent display on particle surfaces improves avidity, while "AND-gate" strategies requiring two binding events can reduce off-target uptake[35]. Stealth coatings—zwitterionic or polysarcosine brushes—limit nonspecific protein adsorption that would otherwise mask ligands.

Companion diagnostics should be co-developed. Quantitative thresholds linking imaging uptake to therapeutic benefit allow enrichment of trials and future clinical use. Machine-learning models that fuse imaging features with clinical variables can forecast responders and guide dose. Importantly, biomarkers must be stable across day-to-day fluctuations common in metabolic disease; fasting state, ambient temperature, and recent meals should be standardized when feasible[36].

Ethical considerations apply: patient selection should avoid systematically excluding groups with different fat distribution or liver phenotypes; accessibility of diagnostics must be maintained. By deliberately pairing ligands with robust biomarkers and practical companion tests, nanotheranostics become deployable precision tools rather than bespoke research curiosities.

4. Stimuli-Responsive and Externally Triggered Theranostic Designs

Stimuli-responsive architectures synchronize diagnosis with therapy by coupling release to microenvironmental cues detected by the same particle. In inflamed adipose, mildly acidic pH (~6.6–7.0), elevated lipase, and increased ROS can cleave acetal, ester, or thioketal linkers, releasing anti-inflammatory agents or mitochondrial modulators[37–40]. Embedding environment-sensing dyes that change signal upon cleavage turns release into a readout, enabling real-time verification of drug liberation. In fibrosing liver, MMP-cleavable peptides or collagen-binding domains concentrate payloads in remodeled matrix, while imaging contrast confirms colocalization.

Glucose-responsive elements extend the concept to glycemia. Phenylboronic acid moieties reversibly bind diols, loosening cross-links as glucose rises and tightening as it falls. When paired with insulin or insulin sensitizers, this creates closed-loop-like control. To avoid interference from other saccharides, chemistries are tuned to physiologic pH and ionic strength[41–43]. Redox-responsive disulfide linkers exploit glutathione gradients inside cells, useful when intracellular targets such as transcriptional co-activators or inflammasome components are engaged.

External triggers add spatiotemporal precision. Focused ultrasound permeabilizes tissue and heats responsive polymers to trigger release, while its imaging capability provides concurrent localization. Photoacoustic/near-infrared light can activate photothermal or photochemical release in superficial depots[44]. Magnetic fields steer superparamagnetic cores and induce local heating for on-demand payload liberation. These triggers enable clinician-controlled dosing synchronized with meals, exercise, or sleep to mitigate hypoglycemia and maximize efficacy[44].

Designing for chronic use requires durability without drift. Responsive motifs must cycle repeatedly without exhausting sensors or fouling. Antifouling surface chemistries prevent protein deposition that would dampen responsiveness. Safety measures include quenching reactive intermediates (e.g., co-encapsulated catalase for GOx-based systems) and preventing thermal damage during external activation[45, 46]. Release profiles should be calibrated against continuous glucose monitoring and energy-expenditure metrics, linking material behavior to clinical outcomes.

By uniting sensing, imaging, and actuation, stimuli-responsive theranostics transform metabolic therapy from static dosing to dynamic, feedback-coupled intervention. This paradigm promises better control with fewer side effects, provided materials are robust, biocompatible, and manufacturable at scale.

5. Safety, Manufacturability, and Regulatory Pathways for Chronic Metabolic Indications

Nanotheranostics intended for long-term metabolic disease must meet a high safety bar. Materials should minimize complement activation and pseudoallergic reactions, especially with repeated dosing[14, 17, 47]. Anti-polymer antibodies historically observed with PEG can alter pharmacokinetics and increase infusion reactions; alternative stealth chemistries such as zwitterionic polymers, polysarcosine, or hydrophilic zwitterionic lipids

mitigate this risk. Particle size, surface charge, and morphology influence uptake by liver and spleen; biodegradable backbones and metabolizable lipids reduce long-term organ retention[48]. Imaging moieties must be tightly chelated or covalently anchored to prevent release; for optical agents, phototoxicity and off-target accumulation require assessment.

Manufacturability hinges on reproducible nanoparticle assembly with narrow polydispersity and consistent payload loading. Scalable processes include microfluidic mixing for lipid systems and controlled nanoprecipitation or emulsion methods for polymers[49]. Critical quality attributes size distribution, zeta potential, drug-to-dye ratio, encapsulation efficiency, residual solvent, endotoxin, and in vitro release, must be specification-controlled with validated assays. Stability programs should test both imaging signal integrity and therapeutic potency under refrigerated and accelerated conditions, including device compatibility where relevant (pens, patches, nebulizers)[49].

Regulatory classification typically falls under combination product frameworks, requiring coordinated chemistry, manufacturing, and controls for the imaging and therapeutic components. Nonclinical packages should include repeat-dose toxicology in metabolically relevant models (diet-induced obesity, both sexes, aged cohorts), biodistribution with quantitative whole-body autoradiography or PET, immunogenicity, and safety pharmacology (cardiovascular, respiratory)[50]. For responsive systems, trigger-specific safety like thermal limits for ultrasound or photothermal activation must be defined. Extractables/leachables from devices and environmental health and safety for manufacturing personnel handling nanomaterials are integral.

Clinical safety monitoring extends beyond standard labs. Ambulatory heart rate and blood pressure, arrhythmia surveillance, and hepatic/renal panels are prudent when adrenergic or mitochondrial pathways are engaged. Imaging dose must be justified; for radionuclides, cumulative exposure should be minimized through low-mass tracers and efficient acquisition. Patient experience matters: injection-site tolerability, scan burden, and device usability influence adherence[50].

Affordability and access are ethical imperatives. Process intensification, solvent minimization, and modular designs that swap ligands or payloads without re-engineering the whole platform can reduce cost. Transparent reporting and cross-trial comparability of imaging endpoints facilitate broader adoption. Meeting these safety and manufacturing standards positions nanotheranostics for durable use in chronic metabolic care.

6. Clinical Translation, Trial Design, and Use Cases in Obesity and Diabetes

A pragmatic clinical roadmap begins with defining use cases where imaging-guided precision alters decisions. One early application is risk enrichment: identifying individuals with disproportionate visceral adipose inflammation or hepatic activity who are likely to progress to diabetes or complications despite similar BMI/HbA1c[51]. A baseline theranostic scan quantifies depot or hepatic uptake; patients above a prespecified threshold enter interventional cohorts receiving localized anti-inflammatory or anti-steatotic payloads. Imaging at weeks 4–12 assesses target engagement and predicts glycemic response, enabling adaptive dosing[51].

For established T2D, theranostics can guide adjunctive therapy. Patients with high hepatic uptake receive liver-targeted insulin sensitizers; those with dominant adipose inflammation receive adipose-directed agents; individuals with microvascular deficits undergo perfusion-enhancing, ultrasound-triggered regimens synchronized with meals or exercise[52]. Continuous glucose monitoring (CGM) provides co-primary outcomes alongside imaging, including time in range, time below range, and glycemic variability. Secondary endpoints include HOMA-IR, tracer-based hepatic glucose production, MRI-PDFF for liver fat, and validated patient-reported outcomes capturing nausea, treatment burden, and quality of life[52].

Phase 1 trials emphasize safety, biodistribution, and dosimetry (for radiolabeled constructs), with crossover comparisons to non-theranostic formulations. Phase 2 adapts doses based on imaging-quantified target engagement, using Bayesian rules to escalate or switch payloads if uptake fails to reach thresholds[53]. Stratification by sex, age, visceral fat fraction, and gastric motility addresses heterogeneity. For externally triggered systems, standardized activation protocols (ultrasound power, duration, timing relative to meals) minimize variability.

Endpoints must link images to outcomes. Pre-specified criteria e.g., ≥30% reduction in depot uptake or ≥3-point increase in muscle perfusion index should correlate with ≥10% improvement in time in range or ≥0.5% HbA1c reduction to qualify as meaningful response[53]. Safety monitoring includes immunogenicity, complement markers, hepatic enzymes, and device-related events. Longer studies assess durability, re-dosing intervals, and whether imaging thresholds shift as tissue remodels.

Real-world deployment could follow two models: centralized imaging centers for PET/MRI-based platforms and clinic-based ultrasound/photoacoustic workflows for superficial depots and triggered release. Integration with digital health automated CGM-theranostic dashboards supports adaptive regimens and patient engagement[53]. Ultimately, success requires demonstrating that imaging-guided therapy delivers equal or better glycemic outcomes with less drug exposure, fewer side effects, and improved patient experience compared with standard care. These evidence standards, if met, can usher nanotheranostics into routine metabolic practice.

CONCLUSIONS

Nanotheranostics merge spatially resolved diagnostics with targeted therapy, directly addressing the heterogeneity that undermines one-size-fits-all care in obesity and diabetes. By homing to inflamed or insulin-

resistant tissues, amplifying multimodal imaging signals, and releasing drugs in response to endogenous cues or external triggers, these platforms enable earlier detection, patient stratification, and adaptive treatment. Thoughtful selection of imaging modalities, ligands, and responsive chemistries paired with rigorous safety, manufacturability, and regulatory planning can translate elegant designs into robust clinical tools. Trials that bind quantitative imaging to CGM-based outcomes will show whether image-guided precision reduces dose, lowers adverse events, and improves everyday life compared with current regimens. Positioned as complements to incretin therapy, SGLT2 inhibitors, and lifestyle interventions, nanotheranostics have the potential to transform metabolic medicine from reactive biomarker management to proactive, mechanism-driven, image-guided care.

REFERENCES

1. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metab. Open. 27, 100375 (2025). https://doi.org/10.1016/j.metop.2025.100375
2. Aldawsari, M., Almadani, F.A., Almuhammadi, N., Algabsani, S., Alamro, Y., Aldhwayan, M.: The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Diabetes Metab. Syndr. Obes. 16, 575–595 (2023). https://doi.org/10.2147/DMSO.S387116
3. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
4. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
5. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 56, 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
6. Behrooz, A.B., Cordani, M., Fiore, A., Donadelli, M., Gordon, J.W., Klionsky, D.J., Ghavami, S.: The obesity-autophagy-cancer axis: Mechanistic insights and therapeutic perspectives. Semin. Cancer Biol. 99, 24–44 (2024). https://doi.org/10.1016/j.semcancer.2024.01.003
7. Assmann, T.S., Riezu-Boj, J.I., Milagro, F.I., Martínez, J.A.: Circulating adiposity-related microRNAs as predictors of the response to a low-fat diet in subjects with obesity. J. Cell. Mol. Med. 24, 2956–2967 (2020). https://doi.org/10.1111/jcmm.14920
8. Bays, H.E., Kirkpatrick, C., Maki, K.C., Toth, P.P., Morgan, R.T., Tondt, J., Christensen, S.M., Dixon, D., Jacobson, T.A.: Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obes. Pillars. 10, 100108 (2024). https://doi.org/10.1016/j.obpill.2024.100108
9. Brown, K.A.: Metabolic pathways in obesity-related breast cancer. Nat. Rev. Endocrinol. 17, 350–363 (2021). https://doi.org/10.1038/s41574-021-00487-0
10. Fuchs, A., Samovski, D., Smith, G.I., Cifarelli, V., Farabi, S.S., Yoshino, J., Pietka, T., Chang, S.-W., Ghosh, S., Myckatyn, T.M., Klein, S.: Associations among adipose tissue immunology, inflammation and exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease. Gastroenterology. 161, 968-981.e12 (2021). https://doi.org/10.1053/j.gastro.2021.05.008
11. Rabizadeh, S., Nakhjavani, M., Esteghamati, A.: Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int. J. Endocrinol. Metab. 17, e84353 (2019). https://doi.org/10.5812/ijem.84353
12. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
13. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
14. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, 21 (2025). https://doi.org/10.3390/jnt6030021
15. Bonlawar, J., Setia, A., Challa, R.R., Vallamkonda, B., Mehata, A.K., Vaishali, Viswanadh, M.K., Muthu, M.S.: Targeted Nanotheranostics: Integration of Preclinical MRI and CT in the Molecular Imaging and Therapy of Advanced Diseases. Nanotheranostics. 8, 401–426 (2024). https://doi.org/10.7150/ntno.95791
16. Guzmán-Sastoque, P., Rodríguez, C.F., Monsalve, M.C., Castellanos, S., Manrique-Moreno, A., Reyes, L.H., Cruz, J.C.: Nanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement. J. Nanotheranostics. 6, 10 (2025). https://doi.org/10.3390/jnt6020010

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

17. Siafaka, P.I., Okur, N.Ü., Karantas, I.D., Okur, M.E., Gündoğdu, E.A.: Current update on nanoplatforms as therapeutic and diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities. Asian J. Pharm. Sci. 16, 24–46 (2021). https://doi.org/10.1016/j.ajps.2020.03.003
18. Abbasi, R., Shineh, G., Mobaraki, M., Doughty, S., Tayebi, L.: Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J. Nanoparticle Res. 25, 43 (2023). https://doi.org/10.1007/s11051-023-05690-w
19. Alfutaimani, A.S., Alharbi, N.K., S. Alahmari, A., A. Alqabbani, A., Aldayel, A.M.: Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids. Int. J. Pharm. X. 8, 100305 (2024). https://doi.org/10.1016/j.ijpx.2024.100305
20. Alimohammadvand, S., Kaveh Zenjanab, M., Mashinchian, M., Shayegh, J., Jahanban-Esfahlan, R.: Recent advances in biomimetic cell membrane–camouflaged nanoparticles for cancer therapy. Biomed. Pharmacother. 177, 116951 (2024). https://doi.org/10.1016/j.biopha.2024.116951
21. Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., Ramesh, R.: Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy. IEEE Trans. Nanobioscience. 15, 849–863 (2016). https://doi.org/10.1109/TNB.2016.2621730
22. Anderson, S.D., Gwenin, V.V., Gwenin, C.D.: Magnetic Functionalized Nanoparticles for Biomedical, Drug Delivery and Imaging Applications. Nanoscale Res. Lett. 14, 188 (2019). https://doi.org/10.1186/s11671-019-3019-6
23. Han, X., Xu, K., Taratula, O., Farsad, K.: Applications of Nanoparticles in Biomedical Imaging. Nanoscale. 11, 799–819 (2019). https://doi.org/10.1039/c8nr07769j
24. Behzadifar, S., Barras, A., Plaisance, V., Pawlowski, V., Szunerits, S., Abderrahmani, A., Boukherroub, R.: Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes. Pharmaceutics. 15, 1215 (2023). https://doi.org/10.3390/pharmaceutics15041215
25. Bollhagen, A., Bodenmiller, B.: Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research. Cancer Discov. 14, 2071–2088 (2024). https://doi.org/10.1158/2159-8290.CD-23-1165
26. Han, S., Lee, D., Kim, S., Kim, H.-H., Jeong, S., Kim, J.: Contrast Agents for Photoacoustic Imaging: A Review Focusing on the Wavelength Range. Biosensors. 12, 594 (2022). https://doi.org/10.3390/bios12080594
27. Awad, N.S., Paul, V., AlSawaftah, N.M., ter Haar, G., Allen, T.M., Pitt, W.G., Husseini, G.A.: Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review. ACS Pharmacol. Transl. Sci. 4, 589–612 (2021). https://doi.org/10.1021/acsptsci.0c00212
28. Foffani, G., Trigo-Damas, I., Pineda-Pardo, J.A., Blesa, J., Rodríguez-Rojas, R., Martínez-Fernández, R., Obeso, J.A.: Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Mov. Disord. Off. J. Mov. Disord. Soc. 34, 1262–1273 (2019). https://doi.org/10.1002/mds.27805
29. Mathon, B., Navarro, V., Pons, T., Lecas, S., Roussel, D., Charpier, S., Carpentier, A.: Ultrasound-induced blood-brain barrier opening and selenium-nanoparticle injection lower seizure activity: A mouse model of temporal lobe epilepsy. Ultrasonics. 155, 107734 (2025). https://doi.org/10.1016/j.ultras.2025.107734
30. Kapoor, M., Heston, T.F., Kasi, A.: PET Scanning. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
31. Ndiaye, D., Tóth, É.: Stable and inert manganese complexes for magnetic resonance imaging. Comptes Rendus Chim. 27, 161–177 (2024). https://doi.org/10.5802/crchim.284
32. Proceedings of the 2023 International Maternal Newborn Health Conference. BMC Proc. 18, 6 (2024). https://doi.org/10.1186/s12919-024-00289-y
33. Zhang, K., Tang, Y., Chen, Q., Liu, Y.: The Screening of Therapeutic Peptides for Anti-Inflammation through Phage Display Technology. Int. J. Mol. Sci. 23, 8554 (2022). https://doi.org/10.3390/ijms23158554
34. Milošević, N., Rütter, M., David, A.: Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines. Front. Med. Technol. 4, 846065 (2022). https://doi.org/10.3389/fmedt.2022.846065
35. Trier, N., Hansen, P., Houen, G.: Peptides, Antibodies, Peptide Antibodies and More. Int. J. Mol. Sci. 20, 6289 (2019). https://doi.org/10.3390/ijms20246289
36. Mankoff, D.A., Edmonds, C.E., Farwell, M.D., Pryma, D.A.: Development of Companion Diagnostics. Semin. Nucl. Med. 46, 47–56 (2016). https://doi.org/10.1053/j.semnuclmed.2015.09.002
37. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
38. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J. Control. Release Off. J. Control. Release Soc. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

39. Khalil, A.K.A., Teow, Y.H., Takriff, M.S., Ahmad, A.L., Atieh, M.A.: Recent developments in stimuli-responsive polymer for emerging applications: A review. Results Eng. 25, 103900 (2025). https://doi.org/10.1016/j.rineng.2024.103900
40. Majumder, J., Minko, T.: Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin. Drug Deliv. 18, 205–227 (2021). https://doi.org/10.1080/17425247.2021.1828339
41. Srivastava, R.: Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines. Nano Trends. 11, 100147 (2025). https://doi.org/10.1016/j.nwnano.2025.100147
42. Yang, J., des Rieux, A., Malfanti, A.: Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 19, 15189–15219 (2025). https://doi.org/10.1021/acsnano.5c00700
43. Zhou, W., Jia, Y., Liu, Y., Chen, Y., Zhao, P.: Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy. Pharmaceutics. 14, 2346 (2022). https://doi.org/10.3390/pharmaceutics14112346
44. Teixeira do Nascimento, A., Stoddart, P.R., Goris, T., Kael, M., Manasseh, R., Alt, K., Tashkandi, J., Kim, B.C., Moulton, S.E.: Stimuli-Responsive Materials for Biomedical Applications. Adv. Mater. 37, e07559 (2025). https://doi.org/10.1002/adma.202507559
45. Wang, J., Li, L., Wu, Y., Liu, Y.: Design and Application of Antifouling Bio-Coatings. Polymers. 17, 793 (2025). https://doi.org/10.3390/polym17060793
46. Zhang, X., Brodus, D., Hollimon, V., Hu, H.: A brief review of recent developments in the designs that prevent bio-fouling on silicon and silicon-based materials. Chem. Cent. J. 11, 18 (2017). https://doi.org/10.1186/s13065-017-0246-8
47. Gawne, P.J., Ferreira, M., Papaluca, M., Grimm, J., Decuzzi, P.: New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics. Nat. Rev. Mater. 8, 783–798 (2023). https://doi.org/10.1038/s41578-023-00581-x
48. Fu, S., Zhu, X., Huang, F., Chen, X.: Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. Pharmaceutics. 17, 1074 (2025). https://doi.org/10.3390/pharmaceutics17081074
49. Prakash, G., Shokr, A., Willemen, N., Bashir, S.M., Shin, S.R., Hassan, S.: Microfluidic Fabrication of Lipid Nanoparticles for the Delivery of Nucleic Acids. Adv. Drug Deliv. Rev. 184, 114197 (2022). https://doi.org/10.1016/j.addr.2022.114197
50. Tian, J., Song, X., Wang, Y., Cheng, M., Lu, S., Xu, W., Gao, G., Sun, L., Tang, Z., Wang, M., Zhang, X.: Regulatory perspectives of combination products. Bioact. Mater. 10, 492–503 (2021). https://doi.org/10.1016/j.bioactmat.2021.09.002
51. Shuster, A., Patlas, M., Pinthus, J.H., Mourtzakis, M.: The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br. J. Radiol. 85, 1–10 (2012). https://doi.org/10.1259/bjr/38447238
52. Zhao, Y., Yue, R.: White adipose tissue in type 2 diabetes and the effect of antidiabetic drugs. Diabetol. Metab. Syndr. 17, 116 (2025). https://doi.org/10.1186/s13098-025-01678-9
53. Jiang, Y., Liu, Q., Wang, G., Zhang, J., Zhu, Z., Chen, X.: Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Clin. Nucl. Med. 48, e289–e293 (2023). https://doi.org/10.1097/RLU.0000000000004642

CITE AS: Katu Amina H. (2026). Nanotheranostics in Obesity and Diabetes: Dual Role in Early Detection and Precision Therapy. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.102108